![]() ![]() Recently he collaborated with Helsinn on the development of the second generation 5-HT3 and NK1 receptor antagonists, palonosetron and netupitant, respectively. ![]() Pioneered the use of the ferret to model chemotherapy-induced acute and delayed emesis (now a gold standard model) and discovered that NK1 tachykinin antagonists could be used to prevent the acute and delayed phases of emesis induced by cisplatin: now NK1 tachykinin antagonists are a cornerstone of treatment for delayed emesis. He was also part of a team that mapped 5-HT3 receptor distribution in the human and ferret brainstem and first to show increases in of 5-HT in the plasma of patients receiving cisplatin-based chemotherapy. RUDD John Anthony (陸臻賢) worked with Glaxo Group Research in the late 1980s to explore the potential use of the 5-HT3 receptor antagonist, ondansetron, to antagonize chemotherapy- and drug-induced emesis. You need JavaScript enabled to view it.ħ04A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK ![]() Featured Interviews and Column ArticlesĮ-mail: This email address is being protected from spambots.SBS Postgraduate Research Day (Restricted download area).SBS Annual Reports and Anniversary Booklets.Students’ and Alumni’s Awards and Updates."Silent Teacher" Body Donation Programme. ![]() Neural, Vascular, and Metabolic Biology.Cancer Biology and Experimental Therapeutics.Career Opportunities at the Dalton laboratory. ![]()
0 Comments
Leave a Reply. |